Sudden Cardiac Death in Heart Failure: A 20-Year Perspective from a Mediterranean Cohort.

BACKGROUND The prediction of sudden cardiac death (SCD) in heart failure (HF) remains an unmet need. The aim of our study was to assess the prevalence of SCD over 20 years in HF outpatients managed in a Mediterranean multidisciplinary HF Clinic, and to compare the proportion of SCD (SCD/all-cause death) to the expected proportional occurrence based on the validated Seattle Proportional Risk Model (SPRM) score. METHODS This prospective observational registry study included 2,772 HF outpatients admitted between August 2001 and May 2021. Patients were included when the cause of death was known and SPRM score was available. RESULTS Over the 20-year study period, 1,351 (48.7%) patients died during a median follow-up period of 3.8 years (interquartile range 1.6-7.6). Among these patients, the proportion of SCD out of the total of deaths was 13.6%, while the predicted by SPRM was 39.6%. This lower proportion of SCD was observed independently of left ventricular ejection fraction, ischemic etiology, and the presence of an implantable cardiac defibrillator. CONCLUSIONS In a Mediterranean cohort of HF outpatients, the proportion of SCD was lower than expected based on the SPRM score. Future studies should investigate to what extend epidemiological and guideline-directed medical therapy patterns influence SCD.

[1]  M. Domingo,et al.  Relationship of Circulating Vegetable Omega-3 to Prognosis in Patients With Heart Failure. , 2022, Journal of the American College of Cardiology.

[2]  J. M. Fernández,et al.  Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial , 2022, The Lancet.

[3]  Deepak L. Bhatt,et al.  Circulating linoleic acid at the time of myocardial infarction and risk of primary ventricular fibrillation , 2022, Scientific Reports.

[4]  Akshay S. Desai,et al.  Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF , 2021, European journal of heart failure.

[5]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. , 2021, European heart journal.

[6]  P. Ponikowski,et al.  Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF , 2021, European heart journal.

[7]  W. Zareba,et al.  Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score. , 2021, European heart journal.

[8]  K. Fukuda,et al.  Prediction of sudden cardiac death in Japanese heart failure patients: international validation of the Seattle Proportional Risk Model. , 2020, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  M. de Antonio,et al.  A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. , 2019, International journal of cardiology.

[10]  M. Domingo,et al.  Trends in modes of death in heart failure over the last two decades: less sudden death but cancer deaths on the rise , 2019, European journal of heart failure.

[11]  A. Brandes,et al.  Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial. , 2019, JACC. Heart failure.

[12]  Prashanthan Sanders,et al.  Epidemiology of Sudden Cardiac Death: Global and Regional Perspectives. , 2019, Heart, lung & circulation.

[13]  George A. Johnson,et al.  Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. , 2018, JACC. Clinical electrophysiology.

[14]  M. de Antonio,et al.  Dynamic Trajectories of Left Ventricular Ejection Fraction in Heart Failure. , 2018, Journal of the American College of Cardiology.

[15]  S. Solomon,et al.  Declining Risk of Sudden Death in Heart Failure , 2017, The New England journal of medicine.

[16]  K. Swedberg,et al.  Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators. , 2017, Journal of the American College of Cardiology.

[17]  C. O'connor,et al.  Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? , 2017, JACC. Clinical electrophysiology.

[18]  Hans Eiskjær,et al.  Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure. , 2016, The New England journal of medicine.

[19]  F. Khan,et al.  Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[20]  D. Mozaffarian,et al.  A novel method to predict the proportional risk of sudden cardiac death in heart failure: Derivation of the Seattle Proportional Risk Model. , 2015, Heart rhythm.

[21]  Akshay S. Desai,et al.  Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. , 2015, European heart journal.

[22]  S. Priori,et al.  Genetics of sudden cardiac death. , 2015, Circulation research.

[23]  F. Gueyffier,et al.  Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials , 2013, BMC Cardiovascular Disorders.

[24]  J. McMurray,et al.  Eplerenone in patients with systolic heart failure and mild symptoms. , 2011, The New England journal of medicine.

[25]  L. Tavazzi,et al.  Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. , 2008, Lancet.

[26]  Douglas L Packer,et al.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.

[27]  G. Billman,et al.  Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. , 2003, Circulation.

[28]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[29]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.